Emmanuel Macron seems to want to give prospects to the French, who were wondering more in recent days if they would eventually end up being re-defined.
What could be better than to give the French a more precise horizon on the vaccination campaign to try to give them a little balm in the heart?
This is what the Head of State strove to do after his meeting with representatives of the players in the vaccine production chain.
Already, Emmanuel Macron has promised that all French people who wish will be able to be vaccinated before the end of the summer.
The commitment, this time, is firm.
It had already been sketched in the mouth of the Minister of Health Olivier Véran last month.
The four sites already identified
But still, Emmanuel Macron announced that the vaccines against Covid-19 will be produced on French soil.
"From the next few weeks, that is to say from the end of February to the beginning of March, we will have sites that will produce the vaccine in France," he announced in front of LCI cameras.
"We will have four that will produce this vaccine," he said.
From Le Parisien, a ministerial source specifies that the sites in question have been "identified and supported for several months".
The four manufacturers who will be responsible for producing the vaccine at one of its sites in France are, according to our information, Recipharm, Delpharm, Fareva and Sanofi.
"The first of them should start producing at the end of February, in March for the Moderna vaccine," said a ministerial source in Le Parisien.
The case of Sanofi is somewhat an exception, since it will focus whatever happens in France on the production of its own vaccine, which is not scheduled for immediately.
It should not be available until the end of the year.
From bottling
Be careful, however, not to be mistaken about the production methods that will actually be implemented on its sites.
At this stage, due to constraints related to the intellectual property of the laboratories which already produce vaccines, the sites requested in France should be satisfied with only packaging, after having received the vaccine already produced elsewhere in the country. world.
“At this stage, it will indeed be bottling.
But it is important to keep in mind that this is a very complex operation, one would like to point out within the executive.
Especially for mRNA vaccines, the molecules of which are very fragile.
We do not improvise flaconneur.
"
At the time of writing this article, it is impossible to know whether the delivery of products to bottling sites by pharmaceutical companies will involve compensation for their benefit.
The objective of the President of the Republic, on the other hand, is well known: "to produce faster and stronger".
And to show, perhaps also, that France can show itself to the initiative on the question of vaccines.
